| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Hans-Christian von Büdingen | Q73517832 |
| P2093 | author name string | Scott S Zamvil | |
| Arumugam Palanichamy | |||
| Klaus Lehmann-Horn | |||
| Brady A Michel | |||
| P2860 | cites work | Atacicept: targeting B cells in multiple sclerosis | Q24628925 |
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| Multiple sclerosis | Q28299151 | ||
| B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells | Q28590517 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Predominant autoantibody production by early human B cell precursors | Q29619656 | ||
| Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response | Q30854079 | ||
| Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. | Q33656297 | ||
| Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. | Q33849373 | ||
| Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease | Q34085036 | ||
| CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients | Q34093165 | ||
| Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 | ||
| Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial | Q34229618 | ||
| Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice | Q34231528 | ||
| Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. | Q34251673 | ||
| Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis | Q34538912 | ||
| Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein | Q34773444 | ||
| Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression | Q34831296 | ||
| Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin | Q34960518 | ||
| B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes | Q35298764 | ||
| Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders | Q35544312 | ||
| Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients | Q35585366 | ||
| Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. | Q54180855 | ||
| TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. | Q54707207 | ||
| Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. | Q54759503 | ||
| Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. | Q55036043 | ||
| Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? | Q57041523 | ||
| Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus | Q57332092 | ||
| Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis | Q61628467 | ||
| Lymphocyte Subpopulations in the Cerebrospinal Fluid and Peripheral Blood in Patients with Multiple Sclerosis | Q66881982 | ||
| A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease | Q68834759 | ||
| Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes | Q72071288 | ||
| Occurrence of oligoclonal IgM bands in the cerebrospinal fluid of neurological patients: an immunoaffinity-mediated capillary blot study | Q72816132 | ||
| B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide | Q73170385 | ||
| Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein | Q74456215 | ||
| Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis | Q79992105 | ||
| Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy | Q81235564 | ||
| BAFF is elevated in serum of patients with Wegener's granulomatosis | Q81389227 | ||
| Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. | Q35769109 | ||
| Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. | Q35835489 | ||
| Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects | Q35907830 | ||
| B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells | Q35946128 | ||
| B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity | Q36034499 | ||
| Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. | Q36385029 | ||
| B cell exchange across the blood-brain barrier in multiple sclerosis | Q36498036 | ||
| The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration | Q36610350 | ||
| Specific peripheral B cell tolerance defects in patients with multiple sclerosis | Q36890946 | ||
| Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation | Q36977531 | ||
| The relation between inflammation and neurodegeneration in multiple sclerosis brains. | Q37181308 | ||
| Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. | Q37285430 | ||
| Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. | Q37385073 | ||
| MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies | Q37397820 | ||
| CD19: a promising B cell target for rheumatoid arthritis | Q37607076 | ||
| In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. | Q37652977 | ||
| New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies | Q37810901 | ||
| The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. | Q37852715 | ||
| Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients | Q38348590 | ||
| Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody | Q41601127 | ||
| B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions | Q41697260 | ||
| Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients | Q42619341 | ||
| A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. | Q42847184 | ||
| B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody | Q42982096 | ||
| Depletion of functionally active CD20+ T cells by rituximab treatment | Q43233232 | ||
| B cells undergo unique compartmentalized redistribution in multiple sclerosis | Q44463732 | ||
| Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation | Q44681284 | ||
| Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial | Q45119459 | ||
| Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study | Q45890653 | ||
| The risk of relapses in multiple sclerosis during systemic infections | Q46129279 | ||
| Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis | Q47309556 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce "oligoclonal bands". | Q48412765 | ||
| Prospective study on the relationship between infections and multiple sclerosis exacerbations | Q48626875 | ||
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment | Q48701331 | ||
| Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. | Q48819558 | ||
| Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis | Q48949365 | ||
| Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis | Q48949792 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Sex ratio of multiple sclerosis in Canada: a longitudinal study. | Q51779582 | ||
| Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. | Q52016419 | ||
| Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. | Q53555780 | ||
| P433 | issue | 3-4 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 238-246 | |
| P577 | publication date | 2015-03-25 | |
| P1433 | published in | European Neurology | Q1376833 |
| P1476 | title | Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets | |
| P478 | volume | 73 |
| Q39458392 | A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model |
| Q58569029 | B Cell Regulation in Autoimmune Diseases |
| Q38702111 | B cell-directed therapies in multiple sclerosis |
| Q40705674 | Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs |
| Q40181000 | EBV Infection Empowers Human B Cells for Autoimmunity: Role of Autophagy and Relevance to Multiple Sclerosis. |
| Q90393310 | Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis |
| Q61817102 | Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use |
| Q89942990 | Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis |
| Q36778303 | High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. |
| Q64968463 | Multiple Sclerosis: B Cells Take Center Stage. |
| Q58555322 | Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? |
| Q37286272 | Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens |
| Q34546457 | The A Allele of the Single-Nucleotide Polymorphism rs630923 Creates a Binding Site for MEF2C Resulting in Reduced CXCR5 Promoter Activity in B-Cell Lymphoblastic Cell Lines |
| Q92302527 | The role of B cells in multiple sclerosis: Current and future therapies |
| Q47191107 | Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator |
| Q38871098 | Unintended Immunological Consequences of Biologic Therapy. |
| Q96306924 | [Ocrelizumab for treatment of multiple sclerosis] |
Search more.